Misa Seki Selected Research

Cerebral Arterial Diseases

7/2022

Effects of Pemafibrate in Patients with Stroke and Hypertriglyceridemia: Baseline Cerebral Artery Diseases and 3-Month Laboratory Outcomes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Misa Seki Research Topics

Disease

1	Atherosclerosis 07/2022
1	Hypertriglyceridemia 07/2022
1	Stroke (Strokes) 07/2022
1	Dyslipidemias (Dyslipidemia) 07/2022
1	Cerebral Arterial Diseases 07/2022
1	Pathologic Constriction (Stenosis) 07/2022
1	Status Epilepticus (Complex Partial Status Epilepticus) 01/2022
1	Unconsciousness (Loss of Consciousness) 01/2022
1	Temporal Lobe Epilepsy 01/2022

Drug/Important Bio-Agent (IBA)

1	(R)-2-(3-((benzoxazol-2-yl-d4 (3- (4- methoxyphenoxy- d7)propyl)amino)methyl)phenoxy) butanoic acidIBA 07/2022
1	Triglycerides (Triacylglycerol)IBA 07/2022
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 07/2022
1	PPAR alphaIBA 07/2022
1	EnzymesIBA 07/2022
1	Levetiracetam (Keppra)FDA LinkGeneric 01/2022
1	fosphenytoin (Cerebyx)FDA LinkGeneric 01/2022
1	Midazolam (Versed)FDA LinkGeneric 01/2022

Therapy/Procedure

1	Therapeutics 07/2022